Gaylor Minh-Ly N, Duvic Madeleine
Louisiana State University Health Sciences Center, New Orleans, USA.
J Drugs Dermatol. 2004 Jan-Feb;3(1):77-9.
Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported. Relapse events can manifest as recurrent plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report a second case of withdrawal flare resulting in generalized pustular psoriasis.
依法利珠单抗是一种针对T淋巴细胞活性的新型生物疗法，用于治疗慢性斑块状银屑病。常见不良反应包括头痛、非特异性感染、恶心、寒战和发热。已有报道称停药后银屑病会出现反弹。复发事件可表现为复发性斑块状银屑病、点滴状银屑病、红皮病型银屑病和脓疱型银屑病。我们报告了第二例停药后病情加重导致泛发性脓疱型银屑病的病例。
